Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anumigilimab in Adults With Sickle Cell Disease
NCT07224360Phase 2Recruiting
- Sponsor
- CSL Limited
- Start
- Feb 2026
- Primary completion
- Aug 2028
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 2 trial of anumigilimab in sickle cell disease (SCD), sponsored by CSL Limited. Started Feb 2026; status: recruiting.
02
Drugs
anumigilimab
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT07224360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07224360.